The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy.

[1]  R. Foà,et al.  Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study , 2020, Leukemia.

[2]  E. Montserrat,et al.  Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty , 2019, Cancer.

[3]  J. Byrd,et al.  Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma , 2019, American journal of hematology.

[4]  F. Merli,et al.  Early Progression As a Predictor of Survival in Marginal Zone Lymphomas: An Analysis from the FIL-NF10 Study. , 2019, Blood.

[5]  Jeffrey A Jones,et al.  Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. , 2019, The Lancet. Haematology.

[6]  J. Byrd,et al.  Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. , 2019, Blood.

[7]  E. M. Cook,et al.  Validation of Clinical Prognostic Models and Integration of Genetic Biomarkers of Drug Resistance in CLL Patients Treated with Ibrutinib , 2018, Blood.

[8]  Jeffrey A Jones,et al.  Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials , 2018, Leukemia & lymphoma.

[9]  E. Kimby,et al.  High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies. , 2018, Blood.

[10]  M. Davids,et al.  Early progression of disease as a predictor of survival in chronic lymphocytic leukemia. , 2017, Blood advances.

[11]  E. Montserrat,et al.  Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL‐IPI , 2017, American journal of hematology.

[12]  A. Wiestner,et al.  Prognostic Models Predictive of Disease Progression in CLL Patients Treated with Ibrutinib , 2016 .

[13]  J. Cerhan,et al.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. , 2016, The Lancet. Oncology.